1. Home
  2. TMCI vs IPHA Comparison

TMCI vs IPHA Comparison

Compare TMCI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Treace Medical Concepts Inc.

TMCI

Treace Medical Concepts Inc.

HOLD

Current Price

$1.76

Market Cap

120.4M

Sector

Health Care

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.49

Market Cap

131.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMCI
IPHA
Founded
2014
1999
Country
United States
France
Employees
N/A
163
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.4M
131.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TMCI
IPHA
Price
$1.76
$1.49
Analyst Decision
Hold
Strong Buy
Analyst Count
6
4
Target Price
$4.77
$5.75
AVG Volume (30 Days)
860.9K
20.9K
Earning Date
05-08-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$212,690,000.00
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
$8.18
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.59
N/A
52 Week Low
$1.17
$1.18
52 Week High
$7.78
$2.63

Technical Indicators

Market Signals
Indicator
TMCI
IPHA
Relative Strength Index (RSI) 50.09 51.87
Support Level $1.24 $1.18
Resistance Level $2.25 $1.80
Average True Range (ATR) 0.21 0.08
MACD -0.00 -0.01
Stochastic Oscillator 32.50 35.00

Price Performance

Historical Comparison
TMCI
IPHA

About TMCI Treace Medical Concepts Inc.

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: